Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS) announced it will call all outstanding Tranche A common stock purchase warrants, giving holders until 6:30 p.m. ET on December 30, 2025 to exercise at $1.05 per share or accept cancellation for $0.00001 per underlying share.
The company has ~17,063,073 Tranche A Warrants outstanding; full exercise would generate up to $17.9 million in gross proceeds before fees. The call was enabled after Fractyl released positive three-month randomized midpoint data from the REMAIN-1 study and met trading conditions, including an average closing price above $1.37 for 15 consecutive trading days; the last reported Nasdaq sale price on December 15, 2025 was $2.24.
Positive
- Up to $17.9M potential gross proceeds if all warrants exercised
- Exercise price $1.05 vs market price $2.24 on Dec 15, 2025
- Clinical milestone: positive three-month randomized midpoint REMAIN-1 data achieved
- Trading milestone: average close >$1.37 for 15 consecutive trading days
Negative
- ~17.06M shares could be issued if all Tranche A Warrants exercised
- Exercise deadline Dec 30, 2025 creates a short, time-limited window for holders
News Market Reaction – GUTS
In the Dec 16 session, GUTS declined 3.57%, reflecting a moderate negative market reaction. Argus tracked a trough of -12.3% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Clinical data update | Positive | +17.9% | Positive 6‑month REVEAL-1 weight maintenance and glycemic durability data. |
| Dec 01 | Conference participation | Neutral | -0.6% | Evercore Healthcare conference fireside chat and investor meetings announcement. |
| Nov 12 | Earnings and pipeline | Positive | +2.7% | Q3 update with positive REMAIN-1 midpoint data and extended cash runway. |
| Nov 05 | Earnings scheduling | Neutral | +0.9% | Announcement of date and webcast details for Q3 2025 results call. |
| Oct 07 | Preclinical obesity data | Positive | -6.8% | Potent RJVA-002 mouse data showing dose-dependent weight loss without adverse effects. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically positive updates and financings have more often been followed by positive or modestly positive price reactions, with only one notable divergence on preclinical news.
This announcement builds on a series of clinically focused updates and financings. In Oct 2025, strong preclinical RJVA-002 obesity data drew a negative reaction. Subsequent Q3 results in Nov 2025 highlighted positive REMAIN-1 midpoint data and extended cash runway, with shares up 2.73%. Early Dec 2025 REVEAL-1 6‑month data drove a 17.95% gain, while an Evercore conference appearance was largely neutral. Earlier offerings in Aug–Sep 2025 raised substantial capital, setting up today’s callable warrant structure tied to REMAIN-1 and trading milestones.
Key Terms
common stock purchase warrants financial
par value financial
registration statement regulatory
Securities and Exchange Commission regulatory
prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Holders will have until December 30, 2025 to exercise Tranche A Warrants at
BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced that it will call all of its outstanding Tranche A Common Stock Purchase Warrants (the “Tranche A Warrants”) to purchase shares of the Company’s common stock, par value
Instead of accepting the nominal consideration for cancellation of their warrants, holders of the Tranche A Warrants may instead elect to exercise their Tranche A Warrants in whole or in part at an exercise price of
As of the date hereof, the Company has approximately 17,063,073 Tranche A Warrants outstanding. The last reported sale price of the Common Stock on The Nasdaq Global Market on December 15, 2025 was
Holders of Tranche A Warrants in “street name” should immediately contact their broker to determine their broker’s procedure for exercising their Tranche A Warrants since the process to exercise is voluntary.
The call was enabled after the Company satisfied the clinical and market performance conditions, including the release of positive three-month randomized midpoint data from the ongoing REMAIN-1 study and the satisfaction of certain trading conditions, including the Common Stock exceeding an average closing price of
Any Tranche A Warrants that remain unexercised immediately after 6:30 p.m., New York City time on the Cancellation Date will be void and no longer exercisable, and the holders of those Tranche A Warrants will be entitled to receive
If all outstanding Tranche A Warrants are exercised prior to the Cancellation Date, Fractyl will receive approximately
The shares of Common Stock underlying the Tranche A Warrants have been registered by Fractyl under the Securities Act of 1933, as amended, and are covered by a registration statement filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”) (File No. 333-285522).
Questions concerning call and exercise of the Tranche A Warrants can be directed to Equiniti Trust Company, LLC, 28 Liberty Street, Floor 53, New York, NY 10005, Attention: Reorganization Department. For a copy of the call notice sent to the holders of the Tranche A Warrants and a prospectus relating to the shares of Common Stock issuable upon exercise of the Tranche A Warrants, please send an email request to IR@fractyl.com.
No Offer or Solicitation
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Fractyl, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 35 granted U.S. patents and approximately 45 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA. For more information, visit www.fractyl.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact are forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, without limitation, statements regarding the call of the Tranche A Warrants. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements are also subject to a number of material risks and uncertainties that are discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 12, 2025 and in our other filings with the SEC. These forward-looking statements are based on management’s current estimates and expectations. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause its views to change.
Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
